Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study.

Zhou Y, Qiao L, Wu J, Hu H, Xu C

Journal of gastroenterology and hepatology1 Sept 2002Cited by 60 (Europe PMC)

PMID12167118DOI10.1046/j.1440-1746.2002.02775.xPepBankPUB-12167118

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In portal hypertensive gastropathy, bleeding control after 48 h occurred in 100% with octreotide versus 14/22 (64%) with vasopressin.
In plain wordsIn portal hypertensive gastropathy, octreotide controlled bleeding in 100% versus 64% with vasopressin after 48 h.
Peptide
Octreotide
Outcome
IncreaseBleeding control versus vasopressin
Study
n: not reported in source
Comparator
Vasopressin
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · infusion · 48 h of infusionAs given in this study (human).
Measurements
Complete bleeding control at 48 h
100%
octreotide group
Complete bleeding control at 48 h
64%
vasopressin group, 14 of 22
Source sentences
Summary
Complete bleeding control after 48 h of drug infusion was achieved in all patients receiving octreotide (100%), 14/22 patients receiving vasopressin (64%), and 13/22 patients receiving Omeprazole (59%).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-eight patients with portal hypertensive gastropathy were randomized into Octreotide, Vasopressin, and Omeprazole groups.
Report a problemFND-1216711801
02HumanRandomized controlled trialEfficacy outcome
In portal hypertensive gastropathy, bleeding control after 48 h occurred in 100% with octreotide versus 13/22 (59%) with omeprazole.
In plain wordsIn portal hypertensive gastropathy, octreotide controlled bleeding in 100% versus 59% with omeprazole after 48 h.
Peptide
Octreotide
Outcome
IncreaseBleeding control versus omeprazole
Study
n: not reported in source
Comparator
Omeprazole
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · infusion · 48 h of infusionAs given in this study (human).
Measurements
Complete bleeding control at 48 h
100%
octreotide group
Complete bleeding control at 48 h
59%
omeprazole group, 13 of 22
Source sentences
Summary
Complete bleeding control after 48 h of drug infusion was achieved in all patients receiving octreotide (100%), 14/22 patients receiving vasopressin (64%), and 13/22 patients receiving Omeprazole (59%).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-eight patients with portal hypertensive gastropathy were randomized into Octreotide, Vasopressin, and Omeprazole groups.
Report a problemFND-1216711802
03HumanRandomized controlled trialEfficacy outcome
In portal hypertensive gastropathy, octreotide required much less time to control bleeding than the other treatment groups (vasopressin, omeprazole); the abstract gives no separate comparison for each.
In plain wordsIn portal hypertensive gastropathy, octreotide controlled bleeding faster than vasopressin and omeprazole, which the abstract does not report separately.
Peptide
Octreotide
Outcome
DecreaseTime to bleeding control
Study
n: not reported in source
Comparator
Vasopressin and omeprazole groups (not reported separately)
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
Octreotide required much less time and significantly fewer blood transfusions to control bleeding.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-eight patients with portal hypertensive gastropathy were randomized into Octreotide, Vasopressin, and Omeprazole groups.
Report a problemFND-1216711803
04HumanRandomized controlled trialEfficacy outcome
In portal hypertensive gastropathy, octreotide required significantly fewer blood transfusions to control bleeding than the other treatment groups (vasopressin, omeprazole); the abstract gives no separate comparison for each.
In plain wordsIn portal hypertensive gastropathy, octreotide needed fewer blood transfusions than vasopressin and omeprazole, which the abstract does not report separately.
Peptide
Octreotide
Outcome
DecreaseBlood transfusions to control bleeding
Study
n: not reported in source
Comparator
Vasopressin and omeprazole groups (not reported separately)
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
Octreotide required much less time and significantly fewer blood transfusions to control bleeding.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-eight patients with portal hypertensive gastropathy were randomized into Octreotide, Vasopressin, and Omeprazole groups.
Report a problemFND-1216711805
05HumanRandomized controlled trialSafety outcome
In portal hypertensive gastropathy, octreotide patients experienced fewer side effects than vasopressin patients.
In plain wordsIn portal hypertensive gastropathy, octreotide patients had fewer side effects than vasopressin patients.
Peptide
Octreotide
Outcome
DecreaseSide effects versus vasopressin
Study
n: not reported in source
Comparator
Vasopressin
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · infusionAs given in this study (human).
Source sentences
Summary
Patients receiving vasopressin experienced more side-effects than those receiving octreotide and omeprazole.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty-eight patients with portal hypertensive gastropathy were randomized into Octreotide, Vasopressin, and Omeprazole groups.
Report a problemFND-1216711807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.